The LDN Book Volume 2 & The Goals of the LDN Research Trust (LDN, low-dose Naltrexone) from LDN Research Trust on Vimeo.

Low Dose Naltrexone (LDN): New in the treatment of chronic pain syndromes. What really matters – reduced pain or increased energy?

Neuro Sciences
15 October 2015
https://www.jns-journal.com/article/S0022-510X(15)01775-X/fulltext

A novel glial cell inhibitor, low dose naltrexone, reduces pain and depression, and improves function in chronic pain: A CHOIR study

J Pain
01 April 2016
http://www.jpain.org/article/S1526-5900(16)00425-9/fulltext

Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants

J Affect Disor
15 January 2017
https://www.ncbi.nlm.nih.gov/pubmed/27736689

Double-blinded placebo-controlled cross-over pilot trial of naltrexone to treat Gulf War Illness

Fatigue: Biomedicine, Health & Behavior
09 June 2018
https://www.tandfonline.com/doi/full/10.1080/21641846.2018.1477034?scroll=top&needAccess=true

Background: 30% of Gulf War veterans developed Gulf War Illness (GWI) with chronic fatigue, pain, and neuropsychological disabilities.

Naltrexone and Scopolamine Rapidly Reduce Symptoms of Major Depressive Disorder (MDD): A Double Blinded Randomized Controlled Pilot Study

Open Journal of Depression
February 2019
https://www.scirp.org/JOURNAL/PaperInformation.aspx?paperID=89841&

Potential antidepressant role of low-dose naltrexone in a rat model of chronic unpredictable mild stress

Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis

Ann Neurol
August 2010
https://pubmed.ncbi.nlm.nih.gov/20695007/

Objective: To evaluate the efficacy of 4.5mg nightly naltrexone on the quality of life of multiple sclerosis (MS) patients.

Low-Dose Naltrexone reduces symptoms in Stiff-Person Syndrome

Med Hypotheses
April 2020
https://pubmed.ncbi.nlm.nih.gov/31954293/

Does Naltrexone Treatment Lead to Depression? Findings From a Randomized Controlled Trial in Subjects With Opioid Dependence (Abstract)

J Psychiatry Neurosci
January 2006
https://pubmed.ncbi.nlm.nih.gov/16496034/

Objective: Dysphoria and depression have been cited as side effects of the opioid antagonist naltrexone. We aimed to assess whether depressive symptoms are a clinically relevant side effect in a population receiving naltrexone as a treatment for opioid dependence.